Therapeutic | Risankizumab |
Target | IL23A |
Heavy Chain | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVADYFCHQYSSYPFTFGSGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2015 |
INN Year Recommended | 2016 |
Companies Involved | AbbVie, Boehringer Ingelheim |
Conditions Approved | Erythrodermic psoriasis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis |
Conditions Active | Crohn's disease, Ulcerative colitis, Atopic dermatitis |
Conditions Discontinued | Psoriasis, Ankylosing spondylitis, Asthma |
Notes |